介孔生物玻璃/磷酸钙骨水泥多级孔复合支架的制备及其载药特性研究

doi:10.3724/SP.J.1077.2013.12301

摘要/Abstract

摘要：

采用离心法将介孔生物活性玻璃(MBG)和磷酸钙骨水泥(CPC)高效复合制备出介孔/大孔多级孔复合支架材料, 评价了其对抗癌药物阿霉素的装载及释放性能。实验结果表明, 采用离心法能在大孔支架CPC内有效负载大量的介孔生物活性玻璃, 使其比表面积高达100.1 m²/g, 负载量达47.2%, 而采用传统浸渍法则不能将MBG粉体材料负载于CPC支架上。载药实验发现离心法制备的介孔/大孔复合支架对阿霉素的装载量达到了46 mg/g, 是普通大孔CPC支架的11.5倍, 且在体外具有药物缓释的特性。

关键词: 离心法, 介孔/大孔, 复合支架, 药物装载, 缓释

Abstract:

Hierarchically composite scaffold (MBG/CPC) was successfully prepared by loading of mesoporous bioactive glasses (MBG) into macroporous calcium phosphate cement (CPC) with simply centrifuging method. It is revealed that MBG loading capacity on CPC and the BET surface area of MBG/CPC can reach 47.2% and 100.1 m²/g, respectively. In contrast, almost no MBG loading is detected by using traditional impregnation route. Drug loading and releasing tests show that DOX loading capacity on hierarchically composite scaffold MBG/CPC is 46 mg/g, which is 11.5 times of that on pure CPC. Importantly, a sustained drug release in vitro performance is presented on MBG/CPC.

Key words: centrifuging, mesoporous/macroporous, composite scaffold, drug loading, sustained release

中图分类号:

TQ174

丁峰, 李楠, 李永生, 施剑林. 介孔生物玻璃/磷酸钙骨水泥多级孔复合支架的制备及其载药特性研究[J]. 无机材料学报, 2013, 28(1): 97-102.

DING Feng, LI Nan, LI Yong-Sheng, SHI Jian-Lin. Preparation of Hierarchically Porous MBG/CPC Scaffold and Its Performance on Drug Loading and Release[J]. Journal of Inorganic Materials, 2013, 28(1): 97-102.

图/表 9

图1 MBG的透射电镜照片(a)和扫描电镜照片(b)

Fig. 1 TEM images of the MBG (a) and SEM images (b) of the MBG

图2 MBG、CPC、MBG/CPC-I以及MBG/CPC-C的小角XRD图谱

Fig. 2 Small-angle XRD patterns of MBG, CPC, MBG/CPC-I and MBG/CPC-C

图3 MBG、CPC、MBG/CPC-I以及MBG/CPC-C的氮气吸附-脱附等温线及BJH孔径分布图(插图) 表1 不同材料的孔结构参数

Fig.3 Nitrogen adsorption-desorption isotherms and pore size distribution curves (inset) of MBG, CPC, MBG/CPC-I and MBG/CPC-C

Table 1 The pore structure parameters of different samples

Sample	BET surface area/(m²·g^-1)	Pore volume /(cm³·g^-1)	BJH pore size/nm
CPC	9.1	0.05	—
MBG	292.9	0.38	5.4
MBG/CPC-I	14.6	0.05	—
MBG/CPC-C	100.1	0.14	5.4

图4 DOX@MBG/CPC-C及DOX@CPC样品装载前后的DOX浸渍溶液的UV-Vis图谱(a)以及DOX@MBG/CPC-C, DOX@CPC和CPC的数码照片(b)

Fig. 4 UV-Vis absorbance spectra of DOX solutions before and after loading for 24 h with MBG/CPC-C and CPC (a); and digital image of DOX@MBG/CPC-C, DOX@CPC and CPC in day-light (b)

图5 不同浓度DOX溶解于PBS中的标准曲线表2 不同材料的DOX装载量

Fig. 5 Calibration curve of the DOX-PBS solutions with different concentrations

Table 2 The DOX loading of different samples

Sample	C₀ /(mg·mL^-1)	C /(mg·mL^-1)	V /mL	m /g	M /(mg·g^-1)
CPC	1.88	1.84	10	0.1	4.0
MBG/CPC-C	1.88	1.42	10	0.1	46.0

图6 不同pH环境下DOX@CPC (a)和DOX@MBG/CPC-C (b)的释放曲线

Fig. 6 pH dependent DOX release from DOX@CPC (a) and DOX@MBG/CPC-C (b) in PBS buffer

图7 MBG, CPC及MBG/CPC-C在SBF中浸泡1 d后的傅里叶变化红外光谱

Fig. 7 FT-IR spectra of MBG, CPC and MBG/CPC-C after soaking in SBF for 1 d

参考文献 23

[1]	Wang T W, Wu H C, Wang W R, et al. The development of magnetic degradable DP-bioglass for hyperthermia cancer therapy. J Biomed Mater Res. A, 2007, 83A(3): 828-837.
[2]	Geraci M, Birch J M, Alston R D, et al. Cancer mortality in 13 to 29-year-olds in England and Wales. Br. J. Cancer, 2007, 97(11): 1588-1594.
[3]	Wang J, Chen P, Liu C. The occurrence, inducement and therapy development of bone cancer. World Journal of Traditional Chinese Orthopedics, 2009, 10(2): 120-121.
[4]	Schulman K L, Kohles J. Economic burden of metastatic bone disease in the US. Cancer, 2007, 109(11): 2334-2342.
[5]	Anderson P, Salazar-Abshire M. Improving outcomes in difficult bone cancers using multimodality therapy, including radiation: Physician and nursing perspectives. Curr. Oncol. Rep., 2006, 8(6): 415-422.
[6]	Nagarajan R, Clohisy D R, Neglia J P, et al. Function and quality- of-life of survivors of pelvic and lower extremity osteosarcoma and Ewing's sarcoma: the childhood cancer survivor study,Br. J. Cancer, 2004, 91(11): 1858-1865.
[7]	Meyer J S, Mackenzie W. Malignant bone tumors and limb-salvage surgery in children. Pediatr. Radiol., 2004, 34(8): 606-613.
[8]	Felder-Puig R, Formann A K, Mildner A, et al. Quality of life and psychosocial adjustment of young patients after treatment of bone cancer. Cancer, 1998, 83(1): 69-75.
[9]	Serrano M C, Portoles M T, Pagani R, et al. In vitro positive biocompatibility evaluation of glass-glass ceramic thermoseeds forhyperthermic treatment of bone tumors. Tissue Eng. A, 2008, 14(5): 617-627.
[10]	Hench L L. Bioceramics: from concept to clinic. J. AM. Ceram. Soc., 1991, 74(7): 1487-1510.
[11]	Hench L L. Bioceramics. J. AM. Ceram. Soc., 1998, 81(7): 1705-1728.
[12]	Arcos D, Greenspan D C, Vallet-Regi M. Influence of the stabilization temperature on textural and structural features and ion release in SiO2-CaO-P2O5 Sol-Gel glasses. Chem. Mater., 2002, 14(4): 1515-1522.
[13]	Jokinen M, Rahiala H, Rosenholm J B, et al. Relation between aggregation and heterogeneity of obtained structure in Sol-Gel derived CaO-P2O5-SiO2. J. Sol-Gel. Sci. Technol., 1998, 12(3): 159-167.
[14]	Lindfors N C, Heikkila J T, Aho A J. Long-term evaluation of blood silicon and ostecalcin in operatively treated patients with benign bone tumors using bioactive glass and autogenous bone. J. Biomed. Mater. Res. B, 2008, 87B(1): 73-76.
[15]	Takegami K, Sano T, Wakabayashi H, et al. New ferromagnetic bone cement for local hyperthermia. J. Biomed. Mater. Res., 1998, 43(2): 210-214.
[16]	Yan X X, Yu C Z, Zhou X F, et al. Highly ordered mesoporous bioactive glasses with superior in vitro bone-forming bioactivities. Angew. Chem. Int. Ed., 2004, 43(44): 5980-5984.
[17]	Xia W, Chang J. Well-ordered mesoporous bioactive glasses (MBG): a promising bioactive drug delivery system. J. Control. Release, 2006, 110(3): 522-530.
[18]	Zhao L Z, Yan X X, Zhou X F, et al. Mesoporous bioactive glasses for controlled drug release. Micropor. Mesopor. Mater., 2008, 109(1/2/3): 210-215.
[19]	Lopez-Noriega A, Arcos D, Izquierdo-Barba I, et al. Ordered mesoporous bioactive glasses for bone tissue regeneration. Chem. Mater., 2006, 18(13): 3137-3144.
[20]	Fang L R, Weng W J, Shen G, et al. Research for bone tissue engineering scaffolds and biomaterials. Journal of Biomedical Engineering, 2003, 20(1): 148-152.
[21]	Zhu M, Wang H X, Liu J Y, et al. A mesoporous silica nanoparticulate/b-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy. Biomaterials, 2011, 32(7): 1986-1995.
[22]	Nielsen O S, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. a study of the EORTC soft tissue and bone sarcoma group. Br. J. Cancer, 1998, 78(12): 1634-1639.
[23]	Guo M, Yan Y, Zhang H K, et al. Magnetic and pH-responsive nanocarriers with multilayer core-shell architecture of anticancer drug delivery. J. Mater. Chem., 2008, 18(42): 5104-5112.